Gene Editing Technology
Steadily, it is very exciting to see that, Gene Editing
Technology is leading to new knowledge, new knowhow, new discoveries, good-living
conditions, development of new therapies and products to benefit mankind.
On this momentum, I have a pleasure to recall
that, the European Patent Office (EPO) intends to grant Dr. Emmanuelle
Charpentier, ERS Genomics’ co-founder, together with the University of
California and University of Vienna, a patent with very broad claims covering
the use of CRISPR-Cas9 technology
for gene editing. 
I can observe that, the claims intended for grant by the EPO are directed to the widely-used single-guide CRISPR-Cas9 gene editing system and cover uses in both cellular and non-cellular settings, including use in bacteria, plants, animals, and cells from vertebrate animals such as humans.
